Daewoong Pharmaceutical's Enblo Receives Approval for Phase 3 Trial of Initial Combination Therapy with Metformin
Phase 3 Clinical Trial Targeting 510 Patients With Type 2 Diabetes
Daewoong Pharmaceutical's type 2 diabetes treatment, Enblo, will begin a phase 3 clinical trial to expand its initial combination therapy with metformin.
On March 5, Daewoong Pharmaceutical announced that it received approval from the Ministry of Food and Drug Safety on March 4 for its phase 3 clinical trial plan (IND) of initial combination therapy with Enblo (active ingredient: inavogliflozin) and metformin hydrochloride extended-release formulation (Metformin XR), aiming to improve blood glucose control in adult patients with type 2 diabetes.
This clinical trial will target adult patients with type 2 diabetes whose blood glucose is not sufficiently controlled by diet and exercise alone. The study has been designed as a multi-center, randomized, double-blind, active-controlled, parallel-group trial.
The purpose of the trial is to confirm whether the therapeutic effect of initial combination therapy with inavogliflozin and metformin is superior to each drug as monotherapy, and to evaluate both efficacy and safety.
A total of 510 patients are expected to participate in the trial. The trial period is planned to last approximately 30 months from the date of approval. Participant recruitment will be conducted on a multinational basis, with some patients to be recruited in Indonesia.
Enblo is a type 2 diabetes treatment in the SGLT-2 inhibitor class developed by Daewoong Pharmaceutical. It is the 36th domestically developed new drug to be approved by the Ministry of Food and Drug Safety in 2022 and is currently being sold in Korea.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Daewoong Pharmaceutical plans to apply for a label change reflecting the results of the initial combination therapy with metformin once the clinical trial is completed. The company expects that, if approved, the combination therapy will help expand treatment options for patients with type 2 diabetes.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.